Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A Timeline of Rising Antisemitism in Australia - 2Trial of pro-Palestine activist begins
- 3Insight: Pills, TikTok, weight-loss apps and the consumer-driven future of GLP-1s
- 4The Beginning Of The End For Fossil Fuels Can Start In Colombia
- 5Independence from the rat race: How to Save and Contribute Shrewdly
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Nature: 10 High priority Setting up camp Spots In Europe
- Hundreds show fascist salute at rally in Rome in annual ritual
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Figure out How to Ascertain the Restitution Time frame for Your Sunlight based chargers
- Red Sea arena: Yemen’s Houthis open fourth front in Iran war, with global implications
- Germany's Bundestag extends two armed forces missions abroad
- Winter solstice 2025 marks the shortest day of the year in the Northern Hemisphere today
